Cargando…

Adoptive immunotherapy for gastric cancer using zoledronate-activated killer cells: A prospective observational study

Mostrar otras versiones (1)

For several years, adoptive immunotherapy (AIT) has been performed using autologous zoledronate-activated killer (ZAK) cells to develop a novel modality for cancer treatment. In the current study, data from 50 patients with incurable gastric cancer were analyzed. Patients were treated with AIT using...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamaguchi, Yoshiyuki, Katata, Yousuke, Sano, Fuminori, Tanioka, Hiroaki, Okawaki, Makoto, Yamamura, Masahiro, Nagasaka, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468212/ https://www.ncbi.nlm.nih.gov/pubmed/32905239 http://dx.doi.org/10.3892/mco.2020.2125

Ejemplares similares

Adoptive immunotherapy for gastric cancer using zoledronate-activated killer cells: A prospective observational study
por: Yamaguchi, Yoshiyuki, et al.
Publicado: (2022)

Neutrophil‑to‑lymphocyte ratio before each chemotherapy line predicts clinical outcomes in patients with unresectable gastric cancer
por: Tanioka, Hiroaki, et al.
Publicado: (2023)

The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY)
por: Tanioka, Hiroaki, et al.
Publicado: (2019)

Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer
por: Taniguchi, Fumitaka, et al.
Publicado: (2021)

Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations
por: Kawai, Takashi, et al.
Publicado: (2021)

Long‐term (>5‐year) survivors among unresectable or metastatic cancer patients treated with zoledronate‐activated killer cells: Seven case reports
por: Yamaguchi, Yoshiyuki
Publicado: (2022)

Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma
por: Kisseberth, William C., et al.
Publicado: (2021)

Natural killer cells in antitumour adoptive cell immunotherapy
por: Laskowski, Tamara J., et al.
Publicado: (2022)

Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy
por: Lupo, Kyle B., et al.
Publicado: (2019)

Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy
por: YOSHIKAWA, TOSHIAKI, et al.
Publicado: (2014)

Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation
por: Nada, Mohanad H., et al.
Publicado: (2017)

Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies
por: Matosevic, Sandro
Publicado: (2018)

Augmentation by Tumor Necrosis Factor α of the Systemic Therapeutic Effect of Lymphokine‐activated Killer Cells in Adoptive Immunotherapy of Murine Tumor
por: Kato, Kazunori, et al.
Publicado: (1991)

Adoptive Immunotherapy Strategies with Cytokine-Induced Killer (CIK) Cells in the Treatment of Hematological Malignancies
por: Schmeel, Frederic Carsten, et al.
Publicado: (2014)

Cytokine-induced killer cells as a feasible adoptive immunotherapy for the treatment of lung cancer
por: Chen, Dan, et al.
Publicado: (2018)

Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer
por: Obajdin, J., et al.
Publicado: (2020)

Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy
por: GRANZIN, MARKUS, et al.
Publicado: (2015)

Adoptive Immunotherapy of Cytokine-Induced Killer Cell Therapy in the Treatment of Non-Small Cell Lung Cancer
por: Wang, Min, et al.
Publicado: (2014)

Natural killer cells modified with a Gpc3 aptamer enhance adoptive immunotherapy for hepatocellular carcinoma
por: Zheng, Youshi, et al.
Publicado: (2023)

Upregulation of microRNA-31 is associated with poor prognosis in patients with advanced colorectal cancer
por: Kubota, Nobuhito, et al.
Publicado: (2020)

Large-scale culture system of human CD4+ helper/killer T cells for the application to adoptive tumour immunotherapy.
por: Nakamura, Y., et al.
Publicado: (1992)

Alloreactive Natural Killer Cells for the Treatment of Acute Myeloid Leukemia: From Stem Cell Transplantation to Adoptive Immunotherapy
por: Ruggeri, Loredana, et al.
Publicado: (2015)

Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid
por: Yanae, Masashi, et al.
Publicado: (2017)

Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy
por: Hazama, Shoichi, et al.
Publicado: (2018)

Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells
por: Ferreira-Teixeira, Margarida, et al.
Publicado: (2016)

Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters
por: Parisi, Sarah, et al.
Publicado: (2022)

An abscopal effect in a case of concomitant treatment of locally and peritoneally recurrent gastric cancer using adoptive T‐cell immunotherapy and radiotherapy
por: Sato, Hiro, et al.
Publicado: (2017)

Natural Killer Cells and Immunotherapy
por: Noh, Ji-Yoon, et al.
Publicado: (2023)

Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C(3)) study
por: Nagasaka, Takeshi, et al.
Publicado: (2016)

Adoptive T Cell Immunotherapy for Cancer
por: Perica, Karlo, et al.
Publicado: (2015)

Adoptive Transfer of Autologous Invariant Natural Killer T Cells as Immunotherapy for Advanced Hepatocellular Carcinoma: A Phase I Clinical Trial
por: Gao, Yao, et al.
Publicado: (2021)

Effect of IL-18 on the Expansion and Phenotype of Human Natural Killer Cells: Application to Cancer Immunotherapy
por: Senju, Hiroaki, et al.
Publicado: (2018)

Immunotherapy: ADOPTIVE T CELL IMMUNOTHERAPY FOR SARS-COV-2
por: Henden, A., et al.
Publicado: (2023)

Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer
por: Shi, Liangrong, et al.
Publicado: (2012)

Natural Killer T Cells in Cancer Immunotherapy
por: Nair, Shiny, et al.
Publicado: (2017)

Natural killer cell immunotherapy in glioblastoma
por: Hosseinalizadeh, Hamed, et al.
Publicado: (2022)

Natural killer cells in tumor immunotherapy
por: Wang, Dongyao, et al.
Publicado: (2023)

Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells
por: Kim, Ji Sung, et al.
Publicado: (2015)

Adoptive immunotherapy with interleukin-2 & induced killer cells in non-small cell lung cancer: A systematic review & meta-analysis
por: Mi, Denghai, et al.
Publicado: (2016)

Comprehensive immunotherapy combined with intratumoral injection of zoledronate-pulsed dendritic cells, intravenous adoptive activated T lymphocyte and gemcitabine in unresectable locally advanced pancreatic carcinoma: a phase I/II trial
por: Hirooka, Yoshiki, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0d2o7gv1vss1gb4b3v5lfp2bon